Daiichi Sankyo has entered into an exclusive licence agreement worth up to $300m with Alteogen to develop a subcutaneous ...

Women aged less than 50 years hospitalized with MI have gender-specific cardiovascular risk factors and experience typical chest pain.

Ideaya Biosciences has decided to go ahead with its plans to grab a bispecific antibody-drug conjugate (ADC) from Biocytogen, exercising an option to pick up a preclinical asset from the Chinese ...

Aileen Lamb, from Edinburgh who had acute myeloid leukaemia said the approval of the new drug gives sufferers hope.

Join Edinburgh Live's Whatsapp Community here and get the latest news sent straight to your messages. Daiichi Sankyo’s drug, quizartinib (Vanflyta) has also been recommended by the SMC for acute ...

Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...

KT&G Corporation ("KT&G" or the "Company") (KRX:033780), announced the 'KT&G Corporate Value-up Plan' on the 7th, that includes their goal of achieving 15% ROE and returning KRW 3.7 trillion to ...

ALT-B4 is Alteogen's proprietary human recombinant hyaluronidase enzyme developed utilizing HybrozymeTM technology. ALT-B4 can enable the large volume subcutaneous administration of drugs that are ...

Alteogen Inc. said that it has entered into an exclusive license agreement with Daiichi Sankyo (DSKYF.PK). As per the terms of the ...

During the 31st APEC Economic Leaders' Meeting in Lima, Peru, this week, a milestone will be reached - the Chancay Port, controlled and invested by Chinese enterprises, is set to hold its operation ...

Butterfly Network, Inc. ("Butterfly") (NYSE: BFLY), a digital health company transforming care through the power of portable, ...